{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:38:15Z","timestamp":1790959095770,"version":"4.1.0"},"reference-count":94,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kom op tegen Kanker (Stand up to Cancer), the Flemish cancer society"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Drug Delivery"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1080\/10717544.2019.1704945","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T11:04:52Z","timestamp":1576839892000},"page":"40-53","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":77,"title":["Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0006-8104","authenticated-orcid":false,"given":"Leen","family":"Van de Sande","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Surgery, Department of Human Structure and Repair, Ghent University, Ghent, Belgium"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-4296","authenticated-orcid":false,"given":"Sarah","family":"Cosyns","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Surgery, Department of Human Structure and Repair, Ghent University, Ghent, Belgium"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0885-6749","authenticated-orcid":false,"given":"Wouter","family":"Willaert","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Surgery, Department of Human Structure and Repair, Ghent University, Ghent, Belgium"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7692-4419","authenticated-orcid":false,"given":"Wim","family":"Ceelen","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Surgery, Department of Human Structure and Repair, Ghent University, Ghent, Belgium"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"e_1_3_3_2_1","first-page":"CD008765","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","author":"Al Rawahi T","year":"2013","unstructured":"Al Rawahi T, Lopes AD, Bristow RE, et\u00a0al. (2013). Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev CD008765.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1021\/am504816h"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.19365"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.89"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.012"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00157.2001"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20010601)92:5<718::AID-IJC1257>3.0.CO;2-D"},{"key":"e_1_3_3_9_1","unstructured":"Carlier C Hoorens A De Clercq K et\u00a0al. (2018). Preclinical activity of two paclitaxel nanoparticle formulations after IP administration in ovarian cancer xenografts. Regional Cancer Therapies 13th International symposium Abstracts. Presented at the 13th International symposium on Regional Cancer Therapies (SSO 2018)."},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2017.1312563"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70335-8"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.217"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0604"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20010217"},{"key":"e_1_3_3_15_1","unstructured":"ClinicalTrials.gov. (2019a). A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01163071 [last accessed 23 Sep 2019]."},{"key":"e_1_3_3_16_1","unstructured":"ClinicalTrials.gov. (2019b). ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00477529 [last accessed 23 Sep 2019]."},{"key":"e_1_3_3_17_1","unstructured":"ClinicalTrials.gov. (2019c). ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03463265 [last accessed 23 Sep 2019]."},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-017-2132-4"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i41.6979"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03767-9"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/1869"},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","unstructured":"D\u2019Cruz O Piacente M Trieu V et\u00a0al. (2010). Abstract 2617: Cardiovascular and CNS safety profile of ABI-013 a novel nanoparticle albumin-bound (nab) analog of docetaxel. Cancer Res 70:2617.","DOI":"10.1158\/1538-7445.AM10-2617"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.07.001"},{"key":"e_1_3_3_24_1","first-page":"351","article-title":"Kinetics of peritoneal fluid absorption in patients with chronic renal failure","volume":"95","author":"Daugirdas JT","year":"1980","unstructured":"Daugirdas JT, Ing TS, Gandhi VC, et\u00a0al. (1980). Kinetics of peritoneal fluid absorption in patients with chronic renal failure. J Lab Clin Med 95:351\u201361.","journal-title":"J Lab Clin Med"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0626-8"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.7.480"},{"key":"e_1_3_3_27_1","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer","volume":"62","author":"Dedrick RL","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT. (1978). Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1\u201311.","journal-title":"Cancer Treat Rep"},{"key":"e_1_3_3_28_1","unstructured":"Desai N. (2008). Nab technology: a drug delivery platform utilising endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting. Drug delivery report winter 2007\/2008 8."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-2116-9_6"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2007.10.008"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2008.04.012"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-0988-1"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198602203140803"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S89066"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.1985.248.1.H15"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1985.248.3.F425"},{"key":"e_1_3_3_37_1","first-page":"H89","article-title":"Peritoneal lymphatic uptake of fibrinogen and erythrocytes in the rat","volume":"244","author":"Flessner MF","year":"1983","unstructured":"Flessner MF, Parker RJ, Sieber SM. (1983). Peritoneal lymphatic uptake of fibrinogen and erythrocytes in the rat. Am J Physiol 244:H89\u201396.","journal-title":"Am J Physiol"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1996.270.2.F377"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00313.2004"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4592"},{"key":"e_1_3_3_41_1","first-page":"13","article-title":"Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy","volume":"7","author":"Goodman MD","year":"2016","unstructured":"Goodman MD, McPartland S, Detelich D, Saif MW. (2016). Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol 7:13.","journal-title":"J Gastrointest Oncol"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.182"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10521"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-018-9895-9"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000171866.45848.68"},{"key":"e_1_3_3_46_1","first-page":"753","article-title":"Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients","volume":"5","author":"Hartung G","year":"1999","unstructured":"Hartung G, Stehle G, Sinn H, et\u00a0al. (1999). Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Clin Cancer Res 5:753\u20139.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.2165\/11598890-000000000-00000"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-195-6"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3222"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.07.011"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8824"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90461-9"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2016.05.005"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2010.10.041"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3210"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2012.03.008"},{"key":"e_1_3_3_57_1","first-page":"17","article-title":"Molecular aspects of ligand binding to serum albumin","volume":"33","author":"Kragh-Hansen U.","year":"1981","unstructured":"Kragh-Hansen U. (1981). Molecular aspects of ligand binding to serum albumin. Pharmacol Rev 33:17\u201353.","journal-title":"Pharmacol Rev"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2008.05.010"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/089686089601601S13"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40591-016-0048-8"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.135.4.2865"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2016.06.012"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0624-7"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2014.00299"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s3061"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41048-018-0079-6"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.09.005"},{"key":"e_1_3_3_68_1","unstructured":"Osborn BL Gu M Grzegorzewski KJ et\u00a0al. (2004). Preliminary pharmacokinetic evaluation of Albuleukin; an interleukin-2 human serum albumin fusion protein in solid tumor patients. AACR Meeting Abstracts 1099-b."},{"key":"e_1_3_3_69_1","first-page":"695","article-title":"Intraoperative hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer","volume":"29","author":"Oseledchyk A","year":"2015","unstructured":"Oseledchyk A, Zivanovic O. (2015). Intraoperative hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer. Oncology (Williston Park, NY) 29:695\u2013701.","journal-title":"Oncology (Williston Park, NY)"},{"key":"e_1_3_3_70_1","doi-asserted-by":"crossref","unstructured":"Pruitt FL Brennen N Antony L et\u00a0al. (2016). Abstract 2076: Albumin-linked proaerolysin based molecular grenades: a systemic therapeutic for disseminated castration resistant prostate cancer. Cancer Res 76:2076.","DOI":"10.1158\/1538-7445.AM2016-2076"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp500394v"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/35077246"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.4281"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2017.04.020"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.140.5.1595"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-016-9791-0"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3213-1"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.2217\/17435889.2.4.415"},{"key":"e_1_3_3_79_1","first-page":"27","article-title":"Synthesis, Characterization and Anti-Cervical Cancer Cell Properties of Bovine Serum Albumen Curcumin Conjugate","volume":"2","author":"Sun C","year":"2014","unstructured":"Sun C, Punia K, Mancuso A, et\u00a0al. (2014). Synthesis, Characterization and Anti-Cervical Cancer Cell Properties of Bovine Serum Albumen Curcumin Conjugate. Biochem Biophys J Neutron Ther Cancer Treat 2:27\u201332.","journal-title":"Biochem Biophys J Neutron Ther Cancer Treat"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2015.07.001"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31825abf8c"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28373"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2016.11.004"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1515\/pp-2018-0112"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-001-0417-z"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.5742"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2009.11.093"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.11.013"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8697"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1620"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2009.07.015"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep31539"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S12918"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201700403"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4936-y"}],"container-title":["Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10717544.2019.1704945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T13:02:47Z","timestamp":1719925367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10717544.2019.1704945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1080\/10717544.2019.1704945"],"URL":"https:\/\/doi.org\/10.1080\/10717544.2019.1704945","relation":{},"ISSN":["1071-7544","1521-0464"],"issn-type":[{"value":"1071-7544","type":"print"},{"value":"1521-0464","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=idrd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=idrd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}